HER VALUE IS INVALUABLE

CGD Nurse Educators, like Irma, help patients start and stay on ACTIMMUNE®

• A dedicated CGD Nurse Educator offers one-on-one support to patients who are either new to treatment or have some treatment experience
• These services are offered at no cost through Horizon Patient Services™

INDICATIONS AND USAGE
ACTIMMUNE® (Interferon gamma-1b) is indicated for reducing the frequency and severity of serious infections associated with chronic granulomatous disease.

Select Important Safety Information
ACTIMMUNE® is contraindicated in patients who develop or have known hypersensitivity to interferon-gamma, E coli-derived products, or any component of the product.

Please see the Important Safety Information on page 4 and the ACTIMMUNE® Full Prescribing Information at ACTIMMUNEhcp.com.

IRMA, CGD Nurse Educator
For patients on ACTIMMUNE® (Interferon gamma-1b)

CGD NURSE EDUCATORS PROVIDE VALUE THROUGHOUT TREATMENT

- Collaborate with your patient’s extended healthcare team
- Provide customized ongoing education about chronic granulomatous disease (CGD) and its treatment
- Manage treatment expectations
- Perform one-on-one injection training
- Serve as a consistent point of contact for your patients
- Encourage and facilitate adherence

VALUABLE SUPPORT SERVICES

Horizon Patient Services provides patients and their families access to a comprehensive network of services and support:

- Works with your office to secure insurance authorizations
- Determines insurance coverage and connects patients with financial assistance, if needed
- Coordinates with the specialty pharmacy to schedule shipments of ACTIMMUNE®
- Sends patients refill reminders via email and/or text
- Helps patients enroll in a sharps disposal program
- Directs patients and their caregivers to social media platforms, peer mentor programs, and live events for people living with CGD and other rare diseases
- Introduces patients to advocacy groups and other community resources

Please see Important Safety Information on page 4 and the ACTIMMUNE® Full Prescribing Information at ACTIMMUNEhcp.com.
It all starts with a kit that will arrive 2 to 3 weeks after a patient or caregiver speaks with a CGD Nurse Educator. The kit is customized for caregivers, young patients, or adult patients, and contains the following:

- **Field guide**—an easy-to-read brochure that helps patients and caregivers understand CGD, prepare for treatment, and recognize the importance of adherence
- **CGD Nurse Educator business card**—a wallet-sized card with contact information, as well as web addresses for other sources of support
- **Injection tracker**—a dry erase board that helps patients and caregivers keep track of injection sites and schedule
- **Leo the Lion**—a brave and cuddly friend to comfort children during injections
- **Travel bag**—an easy-to-carry bag for essential items when traveling or on the go
- **Tote bag**—a carry all for medicine, injection supplies, important medical information, and any other materials needed to keep caregivers organized
- **Desktop organizer**—a box that keeps supplies, such as alcohol swabs, medicine, and injection tracker, all together and easily accessible

Your patients are automatically enrolled in the CGD Nurse Educator Program unless opted out on the Patient Enrollment Form.

To learn more or request a CGD Nurse Educator for your patients, call 1 (877) 305-7704, or visit ACTIMMUNE.com/support.
INDICATIONS AND USAGE
ACTIMMUNE® (Interferon gamma-1b) is indicated:
• For reducing the frequency and severity of serious infections associated with Chronic Granulomatous Disease
• For delaying time to disease progression in patients with severe, malignant osteopetrosis

IMPORTANT SAFETY INFORMATION

CONTRAINDICATIONS
• In patients who develop or have known hypersensitivity to interferon-gamma, E coli-derived products, or any component of the product

WARNINGS AND PRECAUTIONS
• ACTIMMUNE should be used with caution in patients with:
  – Pre-existing cardiac conditions, including ischemia, congestive heart failure, or arrhythmia
  – Seizure disorders or compromised central nervous system function; reduce dose or discontinue
  – Myelosuppression, or receiving other potentially myelosuppressive agents; consider dose reduction or discontinuation of therapy
  – Severe renal insufficiency
  – Age <1 year
• Monitoring:
  – Patients begun on ACTIMMUNE before age 1 year should receive monthly assessments of liver function. If severe hepatic enzyme elevations develop, ACTIMMUNE dosage should be modified
  – Monitor renal function regularly when administering ACTIMMUNE in patients with severe renal insufficiency; accumulation of interferon gamma-1b may occur with repeated administration. Renal toxicity has been reported in patients receiving ACTIMMUNE

• Pregnancy, Lactation, and Fertility:
  – ACTIMMUNE should be used during pregnancy only if the potential benefit outweighs the potential risk to the fetus
  – Use of ACTIMMUNE by lactating mothers is not recommended. ACTIMMUNE or nursing should be discontinued dependent on the importance of the drug to the mother
  – Long-term effects of ACTIMMUNE on fertility are not known

DRUG INTERACTIONS
• Concomitant use of drugs with neurotoxic, hematotoxic, or cardiotoxic effects may increase the toxicity of interferons
• Avoid simultaneous administration of ACTIMMUNE with other heterologous serum protein or immunological preparations (eg, vaccines)

ADVERSE REACTIONS
• The most common adverse experiences occurring with ACTIMMUNE therapy are “flu-like” symptoms such as fever, headache, chills, myalgia, or fatigue, which may decrease in severity as treatment continues, and may be minimized by bedtime administration of ACTIMMUNE. Acetaminophen may be used to prevent or partially alleviate the fever and headache
• Isolated cases of acute serious hypersensitivity reactions have been observed in patients receiving ACTIMMUNE
• Reversible neutropenia, thrombocytopenia, and elevations of AST and/or ALT have been observed during ACTIMMUNE therapy
• At doses 10 times greater than the weekly recommended dose, ACTIMMUNE may exacerbate pre-existing cardiac conditions, or may cause reversible neurological effects such as decreased mental status, gait disturbance, and dizziness

ACTIMMUNE® and Horizon Patient Services™ are owned by or licensed to Horizon. ACTIMMUNE® is distributed in the US by Horizon Pharma USA, Inc. All Rights Reserved ©2019 Horizon Pharma USA, Inc. February 2019 P-ACT-00603

Please see the ACTIMMUNE® Full Prescribing Information at ACTIMMUNEhcp.com.